Your browser doesn't support javascript.
loading
Recessive mutations in ATP8A2 cause severe hypotonia, cognitive impairment, hyperkinetic movement disorders and progressive optic atrophy.
McMillan, Hugh J; Telegrafi, Aida; Singleton, Amanda; Cho, Megan T; Lelli, Daniel; Lynn, Francis C; Griffin, Julie; Asamoah, Alexander; Rinne, Tuula; Erasmus, Corrie E; Koolen, David A; Haaxma, Charlotte A; Keren, Boris; Doummar, Diane; Mignot, Cyril; Thompson, Islay; Velsher, Lea; Dehghani, Mohammadreza; Vahidi Mehrjardi, Mohammad Yahya; Maroofian, Reza; Tchan, Michel; Simons, Cas; Christodoulou, John; Martín-Hernández, Elena; Guillen Sacoto, Maria J; Henderson, Lindsay B; McLaughlin, Heather; Molday, Laurie L; Molday, Robert S; Yoon, Grace.
Afiliación
  • McMillan HJ; Division of Neurology, Department of Pediatrics, Children's Hospital of Eastern Ontario Research Institute, University of Ottawa, Ottawa, ON, Canada.
  • Telegrafi A; GeneDx, Gaithersburg, MD, USA.
  • Singleton A; GeneDx, Gaithersburg, MD, USA.
  • Cho MT; GeneDx, Gaithersburg, MD, USA.
  • Lelli D; Division of Neurology, Department of Medicine, The Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada.
  • Lynn FC; Diabetes Research Program, Child and Family Research Institute, Vancouver, BC, Canada.
  • Griffin J; Department of Surgery and Department of Cellular and Physiological Sciences, University of British Columbia, Vancouver, BC, Canada.
  • Asamoah A; Weisskopf Child Evaluation Center, Department of Pediatrics, School of Medicine, University of Louisville, Louisville, KY, USA.
  • Rinne T; Weisskopf Child Evaluation Center, Department of Pediatrics, School of Medicine, University of Louisville, Louisville, KY, USA.
  • Erasmus CE; Department of Human Genetics, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Koolen DA; Department of Neurology, Donders Center of Neuroscience, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Haaxma CA; Department of Human Genetics, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Keren B; Department of Neurology, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Doummar D; Assistance Publique Hôpitaux de Paris, Département de Génétique, Groupe Hospitalier, Pitié-Salpêtrière, Paris, France.
  • Mignot C; Service de Neuropédiatrie, Hôpital Armand-Trousseau, Paris, France.
  • Thompson I; Assistance Publique Hôpitaux de Paris, Département de Génétique, Groupe Hospitalier, Pitié-Salpêtrière, Paris, France.
  • Velsher L; Centre de Référence Déficiences Intellectuelles de Causes Rares, GH Pitié Salpêtrière, Paris, France.
  • Dehghani M; Groupe de Recherche Clinique UPMC Déficience Intellectuelle de Causes Rares et Autisme GH Pitié-Salpêtrière, Paris, France.
  • Vahidi Mehrjardi MY; Genetics Program, North York General Hospital, Toronto, ON, Canada.
  • Maroofian R; Genetics Program, North York General Hospital, Toronto, ON, Canada.
  • Tchan M; Medical Genetics Research Centre, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
  • Simons C; Reproductive Sciences Institute, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
  • Christodoulou J; Reproductive Sciences Institute, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
  • Martín-Hernández E; Diabetes Research Centre, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
  • Guillen Sacoto MJ; Human Genetics Research Centre, Molecular and Clinical Sciences Institute, St George's University of London, London, UK.
  • Henderson LB; Department of Genetic Medicine, Westmead Hospital, Westmead, NSW, Australia.
  • McLaughlin H; Sydney Medical School, University of Sydney, Sydney, NSW, Australia.
  • Molday LL; Institute for Molecular Bioscience, University of Queensland, St Lucia, QLD, Australia.
  • Molday RS; Neurodevelopmental Genomics Research Group, Murdoch Childrens Research Institute and Department of Paediatrics, Melbourne Medical School, University of Melbourne, Melbourne, VIC, Australia.
  • Yoon G; Unidad de Enfermedades Mitocondriales-Metabólicas Hereditarias, Servicio de Pediatría Hospital Universitario 12 de Octubre, Universidad Complutense de Madrid, Madrid, Spain.
Orphanet J Rare Dis ; 13(1): 86, 2018 05 31.
Article en En | MEDLINE | ID: mdl-30012219
BACKGROUND: ATP8A2 mutations have recently been described in several patients with severe, early-onset hypotonia and cognitive impairment. The aim of our study was to characterize the clinical phenotype of patients with ATP8A2 mutations. METHODS: An observational study was conducted at multiple diagnostic centres. Clinical data is presented from 9 unreported and 2 previously reported patients with ATP8A2 mutations. We compare their features with 3 additional patients that have been previously reported in the medical literature. RESULTS: Eleven patients with biallelic ATP8A2 mutations were identified, with a mean age of 9.4 years (range 2.5-28 years). All patients with ATP8A2 mutations (100%) demonstrated developmental delay, severe hypotonia and movement disorders, specifically chorea or choreoathetosis (100%), dystonia (27%) and facial dyskinesia (18%). Optic atrophy was observed in 78% of patients for whom funduscopic examination was performed. Symptom onset in all (100%) was noted before 6 months of age, with 70% having symptoms noted at birth. Feeding difficulties were common (91%) although most patients were able to tolerate pureed or thickened feeds, and 3 patients required gastrostomy tube insertion. MRI of the brain was normal in 50% of the patients. A smaller proportion was noted to have mild cortical atrophy (30%), delayed myelination (20%) and/or hypoplastic optic nerves (20%). Functional studies were performed on differentiated induced pluripotent cells from one child, which confirmed a decrease in ATP8A2 expression compared to control cells. CONCLUSIONS: ATP8A2 gene mutations have emerged as the cause of a novel neurological phenotype characterized by global developmental delays, severe hypotonia and hyperkinetic movement disorders, the latter being an important distinguishing feature. Optic atrophy is common and may only become apparent in the first few years of life, necessitating repeat ophthalmologic evaluation in older children. Early recognition of the cardinal features of this condition will facilitate diagnosis of this complex neurologic disorder.
Asunto(s)
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Atrofia Óptica / Adenosina Trifosfatasas / Proteínas de Transferencia de Fosfolípidos / Disfunción Cognitiva / Hipotonía Muscular / Mutación Tipo de estudio: Etiology_studies / Observational_studies Idioma: En Revista: Orphanet J Rare Dis Asunto de la revista: MEDICINA Año: 2018 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Atrofia Óptica / Adenosina Trifosfatasas / Proteínas de Transferencia de Fosfolípidos / Disfunción Cognitiva / Hipotonía Muscular / Mutación Tipo de estudio: Etiology_studies / Observational_studies Idioma: En Revista: Orphanet J Rare Dis Asunto de la revista: MEDICINA Año: 2018 Tipo del documento: Article